Linoladiol N (Estradiol Hemihydrate)

Estradiol hemihydrate binds to estrogen receptors in target tissues, forming a complex that regulates gene transcription. This promotes proliferation of the vaginal epithelium, increases mucosal secretions, and restores tissue elasticity, providing estrogenic effects that counteract menopausal changes.

The appropriate dose of Linoladiol N is determined by the prescribing healthcare professional based on the individual’s clinical condition, severity of symptoms, and response to therapy. No fixed regimen is provided here.

The safety of estradiol hemihydrate during pregnancy or lactation has not been established. It is generally contraindicated in pregnant or breastfeeding women unless the benefits clearly outweigh the risks, and a healthcare provider should be consulted.

To order Linoladiol N, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Linoladiol N delivers estradiol hemihydrate via a vaginal route, offering localized estrogen effects with lower systemic exposure compared with oral or transdermal preparations. This can result in fewer systemic side effects while effectively treating vaginal atrophy, making it a preferred option for patients needing targeted therapy.

Linoladiol N should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Linoladiol N is administered intravaginally. The prescribed tablet or applicator is inserted into the vagina according to the healthcare provider’s instructions, typically at bedtime or as directed, to ensure optimal absorption and therapeutic effect.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe allergic reactions that may lead to anaphylaxis, and endometrial hyperplasia, which can increase the risk of uterine cancer. Patients should be monitored for any signs of these conditions.

Linoladiol N should not be used by individuals with a history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active thromboembolic disease, severe liver dysfunction, or known hypersensitivity to estradiol or any excipients in the formulation.